Tarride Jean-Eric, Prajapati Vimal H, Lynde Charles, Blackhouse Gord
Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Programs for Assessment of Technology in Health (PATH), The Research Institute of St. Joe's Hamilton, St. Joseph's Healthcare Hamilton, Hamilton, Canada.
JAAD Int. 2023 Apr 14;12:90-98. doi: 10.1016/j.jdin.2023.03.012. eCollection 2023 Sep.
Not much is known about the burden of generalized pustular psoriasis (GPP).
To document the burden of GPP in Canada and to compare it with psoriasis vulgaris (PV).
National data were used to identify Canadian adult patients with GPP or PV hospitalized or visiting an emergency department (ED) or hospital-/community-based clinic between April 1, 2007, and March 31, 2020. Analyses of 10-year prevalence and 3-year incidence were conducted. Costs were determined when the most responsible diagnosis (MRD) was GPP or PV (MRD costs) and for all reasons (all-cause costs).
In the prevalence analysis, 10-year mean (SD) MRD costs were $2393 ($11,410) for patients with GPP and $222 ($1828) for those with PV ( < .01). In the incidence analysis, patients with GPP had higher 3-year mean (SD) MRD costs ($3477 [$14,979] vs $503 [$2267] for PV; < .01). Higher all-cause costs were also associated with patients with GPP. Inpatient/ED mortality was higher in the GPP group in our 10-year prevalence (9.2% for patients with GPP vs 7.3% for those with PV; = .01) and 3-year incidence (5.2% for patients with GPP and 2.1% for those with PV; = .03) analyses.
Physician and prescription drug data were not available.
Patients with GPP incurred higher costs and mortality than patients with PV.
关于泛发性脓疱型银屑病（GPP）的负担了解不多。
记录加拿大GPP的负担，并将其与寻常型银屑病（PV）进行比较。
利用全国数据确定2007年4月1日至2020年3月31日期间在加拿大住院或前往急诊科（ED）或医院/社区诊所就诊的成年GPP或PV患者。进行了10年患病率和3年发病率分析。当最主要诊断（MRD）为GPP或PV时确定费用（MRD费用）以及所有原因导致的费用（全因费用）。
在患病率分析中，GPP患者10年平均（标准差）MRD费用为2393美元（11410美元），PV患者为222美元（1828美元）（<0.01）。在发病率分析中，GPP患者3年平均（标准差）MRD费用更高（GPP为3477美元[14979美元]，PV为503美元[2267美元]；<0.01）。GPP患者的全因费用也更高。在我们的10年患病率（GPP患者为9.2%，PV患者为7.3%；P = 0.01）和3年发病率（GPP患者为5.2%，PV患者为2.1%；P = 0.03）分析中，GPP组的住院/ED死亡率更高。
没有医生和处方药数据。
GPP患者比PV患者产生更高的费用和死亡率。
